Epirubicin as adjuvant therapy in breast cancer

Expert Review of Anticancer Therapy

Volumn 4, Issue 2, 2004, Pages 189-195

  Earl, Helena ^a   Iddawela, Mahesh ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adjuvant chemotherapy; Anthracyclines; Early breast cancer; Epirubicin; Survival

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALOPECIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG STRUCTURE; EARLY CANCER; FEBRILE NEUTROPENIA; HEART FAILURE; HUMAN; LEUKEMIA; METASTASIS; NAUSEA; NEUTROPENIA; REVIEW; SEPSIS; STOMATITIS; VOMITING;

EID: 1842689603     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.2.189     Document Type: Review

References (29)

1. National Statistics Office. Breast cancer: Incidence Rate Rises While Death Rate Falls. National Statistics Office, UK (2003).
2. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J. Clin. Oncol. 19, 3817-3827 (2001).
3. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer, the results of 20 years of follow-up. N. Engl. J. Med. 332, 901-906 (1995).
4. Early Breast Cancer Trialists' Collaborative Group (EBCTC). Poly-chemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352, 930-942 (1998).
5. Smith PJ, Soues S. Multilevel therapeutic targeting by topoisomerase inhibitors. Br. J. Cancer 23, S47 (1994).
6. Robert J. Clinical pharmacokinetics of epirubicin. Clin. Pharmacokinet. 26, 428-438 (1994).
7. French Epirubicin Study Group. A prospective randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J. Clin. Oncol. 6, 679-688 (1988).
8. Italian Multicenter Breast Study with Epirubicin Group. Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide vs. fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: an Italian multicenter trial. J. Clin. Oncol. 6, 976-982 (1988).
9. Lopez M, Papaldo O, Di Lauro L et al. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology 46, 1-5 (1989).
10. Heidemann E, Steinke B, Harlapp J et al. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Onkologie 13, 24-27 (1990).
11. Lawton PA, Spittle MF, Ostrowski MJ et al. A comparison of doxorubicin, epirubicin and mitoxantrone as single agents in advanced breast carcinoma. J. Clin. Oncol. 5, 80-44 (1993).
12. Poole CJ, Earl HM, Dunn JA et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR 9601 (Scottish Cancer Trials breast group) Phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc. Am. Soc. Clin. Oncol. 22, 4 (2003) (Abstract 13).
13. Coombes RC, Bliss JM, Wils J et al. Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. The International Collaborative Cancer Group. J. Clin. Oncol. 14, 35-45 (1996).
14. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 16, 2651-2658 (1998).
15. Mouridsen HT, Andersen J, Andersson M et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc. Am. Soc. Clin. Oncol. 18, 68a (1999) (Abstract 254).
16. Piccart MJ, Di Leo A, Beauduin M et al. Phase III trial comparing two dose levels of epirubicin combined with epirubicin, with cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. J. Clin. Oncol. 19, 3103-3110 (2001).
17. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol. 19, 602-611 (2001).
18. Fumoleau P, Kerbrat P, Romestaing P et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node positive breast cancer patients: 10 year follow-up results of the FASG 01 trial. J. Clin. Oncol. 21, 298-305 (2003).
19. Basholt L, Dalmark M, Gjedde SB et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Co-operative Group. J. Clin. Oncol. 4, 1146-1155 (1996).
20. Earl HM, Poole CJ, Dunn JA et al. on behalf of the NEAT Steering Cominittee. Tolerability (toxicity, dose intensity and quality adjusted survival (QAS)) of ECMF versus CMF in the National Epirubicin Adjuvant Trial (NEAT) in moderate risk early breast cancer. Breast Cancer Res. Treat. 76(1), 647 (2002).
21. Mouridsen HT, Alfthan C, Bastholt L et al. Current status of epirubicin (Farmourubicin) in the treatment of solid tumors. Acta Oncol. 29, 257-285 (1990).
22. Tokarska-Schlattner M, Wallimann T, Schlattner U. Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol. Pharm. 61(3), 516-523 (2002).
23. Herait P, Poutignat N, Martyn M et al. Early assessment of a new anticancer drug analogue: Are the historical comparisons obsolete? The French experience with pirarubicin. Eur. J. Cancer 28A, 1670-1676 (1992).
24. Ryberg M, Nielsen D, Skovsgaard T et al. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. 6(11), 3502-3508 (1998).
25. Curtis RE, Boice JD, Stovall M et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N. Engl. J. Med. 326, 1745-1751 (1992).
26. Allan JM, Wild CP, Rollinson S et al. Polymorphisms in glutathione S-transferase Pl is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl Acad. Sci. US4 98(20), 11592-11597 (2001).
27. Crump M, Tu D, Shepherd L et al. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3066-3071 (2003).
28. Diamandidou E, Buzdar AU, Smith TL et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas MD Anderson Cancer Center Experience. J. Clin. Oncol. 12, 2722-2730 (1996).
29. Bernard-Marty C, Mano M, Paesmans M et al. Second malignancies following chemothrapy: 6-year results from the Belgian randomized study comparing cyclophosphamide, methotrexate and 5-flourouracil (CMF) with anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann. Oncol. 14, 693-698 (2003).